scholarly journals Local and systemic delivery of mRNA encoding survivin-T34A by lipoplex for efficient colon cancer gene therapy

2019 ◽  
Vol Volume 14 ◽  
pp. 2733-2751 ◽  
Author(s):  
Xueyan Zhang ◽  
Ke Men ◽  
Yuanfa Zhang ◽  
Rui Zhang ◽  
Li Yang ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Colon Cancer ◽  
Cancer Gene Therapy ◽  
Cancer Gene ◽  
Systemic Delivery

scholarly journals Delivery of modified mRNA encoding vesicular stomatitis virus matrix protein for colon cancer gene therapy

RSC Advances ◽  
2018 ◽  
Vol 8 (22) ◽  
pp. 12104-12115 ◽  
Author(s):  
Ke Men ◽  
Rui Zhang ◽  
Xueyan Zhang ◽  
Rong Huang ◽  
Guonian Zhu ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Colon Cancer ◽  
Colon Carcinoma ◽  
Vesicular Stomatitis Virus ◽  
Matrix Protein ◽  
Cancer Gene Therapy ◽  
Viral Gene ◽  
Cancer Gene ◽  
Viral Gene Therapy ◽  
Vesicular Stomatitis

Liposome–protamine complex delivered VSVMP mRNA efficiently inhibits C26 colon carcinoma with safety, providing an alternative strategy for non-viral gene therapy.

Cells as Vehicles for Cancer Gene Therapy: The Missing Link Between Targeted Vectors and Systemic Delivery?

2002 ◽  
Vol 13 (11) ◽  
pp. 1263-1280 ◽  
Author(s):  
Kevin Harrington ◽  
Luis Alvarez-Vallina ◽  
Marka Crittenden ◽  
Michael Gough ◽  
Heung Chong ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Cancer Gene Therapy ◽  
Cancer Gene ◽  
Systemic Delivery ◽  
Missing Link

Delivery of a Modified mRNA Encoding IL-22 Binding Protein (IL-22BP) for Colon Cancer Gene Therapy

2018 ◽  
Vol 14 (7) ◽  
pp. 1239-1251 ◽  
Author(s):  
Rui Zhang ◽  
Ke Men ◽  
Xueyan Zhang ◽  
Rong Huang ◽  
Yaomei Tian ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Colon Cancer ◽  
Binding Protein ◽  
Cancer Gene Therapy ◽  
Cancer Gene

scholarly journals A novel colon cancer gene therapy using rAAV-mediated expression of human shRNA-FHL2

2013 ◽  
Vol 43 (5) ◽  
pp. 1618-1626 ◽  
Author(s):  
YAO WU ◽  
ZHENG GUO ◽  
DI ZHANG ◽  
WENJING ZHANG ◽  
QINGQING YAN ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Colon Cancer ◽  
Cancer Gene Therapy ◽  
Cancer Gene

scholarly journals Cationic micelle-based siRNA delivery for efficient colon cancer gene therapy

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Yongping Lu ◽  
Lei Zhong ◽  
Zhongliang Jiang ◽  
Haixia Pan ◽  
Yuanfa Zhang ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Colon Cancer ◽  
Sirna Delivery ◽  
Cancer Gene Therapy ◽  
Cancer Gene

scholarly journals Delivery of interleukin-22 binding protein (IL-22BP) gene by cationic micelle for colon cancer gene therapy

RSC Advances ◽  
2018 ◽  
Vol 8 (30) ◽  
pp. 16537-16548 ◽  
Author(s):  
Ke Men ◽  
Rong Huang ◽  
Xueyan Zhang ◽  
Rui Zhang ◽  
Yuanfa Zhang ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Colon Cancer ◽  
Colon Carcinoma ◽  
Binding Protein ◽  
Cancer Gene Therapy ◽  
Cancer Gene ◽  
Interleukin 22 ◽  
Novel Strategy

Cationic DMP micelle delivered interleukin-22BP gene efficiently inhibits colon carcinoma growth, providing a novel strategy for cancer gene therapy.

Enhanced Suppression of Disulfide Cross-Linking Micelles Nanocarriers Loaded miR-145 Delivering System via Down-Regulation of MYC and FSCN1 in Colon Cancer Cells

2020 ◽  
Vol 16 (8) ◽  
pp. 1183-1195
Author(s):  
Jingming Zhai ◽  
Yanliang Zhu ◽  
Jiangbo Liu ◽  
Junling An ◽  
Yingjie Yu ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Colon Cancer ◽  
Cancer Cells ◽  
Complex Disease ◽  
Cancer Gene Therapy ◽  
Cross Linking ◽  
Cancer Gene ◽  
Colon Cancer Cells ◽  
Hct 116

Colorectal carcinoma is a complex disease accounting for adenoma tumors and an aggressive phenotype, and the third leading cause of cancer death. In the past decades, miRNAs have been associated with molecular pathways of cancer and other diseases. The dysregulated miRNAs play an inhibitory or promoting role in tumorigenesis. Therefore, restoration of tumor-suppressed microRNAs (miRNA) may offer novel therapeutic approaches for cancer treatment. Nevertheless, the poor bioavailability of miRNA due to their rapid enzymatic degradation is a critical barrier in cancer gene therapy. To overcome this dilemma, we designed disulfide cross-linking micelles (DCM) nanocarrier for delivery of miR-145 to colon cancer cells and investigated its therapeutic efficacy in vitro and in vivo. Results indicated that the presence of DCM nanocarrier loaded with miR-145 enhanced selective delivery of miR-145 and facilitated cellular uptake, significantly up-regulating miR-145 expression in HCT-116 cell lines. Consequently, the cell proliferation was inhibited by arresting cell cycle at the G1 phase. Further, apoptosis of HCT-116 cells treated with miR-145 complex nanoparticles may be via downregulation of oncogenes MYC and FSCN1, predicting regulatory targets for miR-145. These results pave the way for further investigations into the potential of miR-145 complex nanocarrier for cancer gene therapy.

Sign in / Sign up

Export Citation Format

Share Document